Compare stocks

BFLY vs TLSI

Butterfly Network, Inc. and TriSalus Life Sciences, Inc. Common Stock

Compare the businesses

Butterfly Network, Inc.

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly iQ+ Bladder, a specialty product for the bladder scanning market; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. It also provides Butterfly system, which includes probes, related accessories, and software subscriptions to healthcare systems, physicians, and healthcare providers. In addition, the company offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments; and ScanLab, an education-only app that provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. It sells its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Open BFLY dashboard ↗

TriSalus Life Sciences, Inc. Common Stock

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Open TLSI dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗